To this end, the present research was performed to evaluate the serum markers associated with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with lung adenocarcinoma and bone metastases, specifically focusing on the prognostic value of EGFR-TKI therapy. The gene discussed is EGFR; the disease is lung adenocarcinoma.